Skip to content

Clinical trials

Phase 4 Coronary Artery Disease trials in China

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Coronary Artery Disease Phase: Phase 4 Country / region: China Clear all

62 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20041
20061
20071
20081
20091
20104
20115
20123
20135
20143
20154
20162
20173
20186
20194
20202
20213
20221
20233
20242
20254
20263

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed25
Unknown status25
Recruiting11
Not yet recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
China National Center for Cardiovascular Diseases5
The First Affiliated Hospital with Nanjing Medical University5
Shanghai Jiao Tong University School of Medicine4
Abbott Medical Devices3
Beijing Anzhen Hospital3
Peking Union Medical College Hospital3
First Affiliated Hospital of Harbin Medical University2
Harbin Medical University2
Nanjing First Hospital, Nanjing Medical University2
Shenyang Northern Hospital2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Coronary Artery Disease62
Coronary Disease7
Diabetes Mellitus, Type 26
Acute Coronary Syndrome5
Myocardial Ischemia5
Hyperlipidemias4
Vascular Diseases4
Coronary Restenosis3
Coronary Stenosis3
Atrial Fibrillation2

Trials

Showing 1 to 25 of 62. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.